First Time Loading...
M

Maccura Biotechnology Co Ltd
SZSE:300463

Watchlist Manager
Maccura Biotechnology Co Ltd
SZSE:300463
Watchlist
Price: 13.19 CNY -1.2% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

8.1B
-1%
Assets
Growth Rates:
1 Year
-1%
3 Years
+28%
5 Years
+78%
7 Years
+201%
10 Years
-
1.7B
-9%
Liabilities
Growth Rates:
1 Year
-8%
3 Years
-32%
5 Years
-7%
7 Years
+281%
10 Years
-
6.4B
+0.8%
Equity
Growth Rates:
1 Year
+1%
3 Years
+68%
5 Years
+137%
7 Years
+185%
10 Years
-

Balance Sheet Decomposition
Maccura Biotechnology Co Ltd

8.1B
Assets
1.7B
Liabilities
8.1B
Assets
1.7B
Liabilities
Current Assets 4.2B
Cash & Short-Term Investments 1.1B
Receivables 2B
Other Current Assets 1.1B
Non-Current Assets 3.9B
Long-Term Investments 239.2m
PP&E 2.9B
Intangibles 565.9m
Other Non-Current Assets 162.4m
Current Liabilities 1.1B
Accounts Payable 285.4m
Accrued Liabilities 146.8m
Short-Term Debt 225.1m
Other Current Liabilities 463.3m
Non-Current Liabilities 613.8m
Long-Term Debt 175.5m
Other Non-Current Liabilities 438.3m

Balance Sheet
Maccura Biotechnology Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
178
201
154
338
390
430
583
616
564
811
Cash
0
0
0
0
0
0
0
616
564
811
Cash Equivalents
178
201
154
338
390
430
583
0
0
0
Short-Term Investments
0
0
0
0
0
0
0
0
664
311
Total Receivables
392
603
827
1 198
1 637
2 063
2 205
2 034
2 261
1 974
Accounts Receivables
388
579
790
1 126
1 479
1 920
2 021
1 882
2 074
1 773
Other Receivables
4
24
37
72
158
143
184
152
188
201
Inventory
191
267
359
548
731
852
1 075
1 076
1 039
907
Other Current Assets
50
709
409
235
203
162
163
129
169
218
Total Current Assets
810
1 780
1 749
2 318
2 961
3 506
4 025
3 855
4 698
4 222
PP&E Net
364
517
786
1 047
1 303
1 597
1 742
2 015
2 513
2 929
PP&E Gross
364
517
786
1 047
1 303
1 597
1 742
2 015
2 513
2 929
Accumulated Depreciation
108
152
208
254
352
470
591
708
845
1 006
Intangible Assets
14
22
86
101
149
211
246
281
374
421
Goodwill
0
0
4
21
21
21
21
21
145
145
Note Receivable
10
10
14
10
6
1
0
0
0
0
Long-Term Investments
8
26
30
30
30
41
141
221
262
239
Other Long-Term Assets
11
18
30
54
86
120
190
173
176
162
Other Assets
0
0
4
21
21
21
21
21
145
145
Total Assets
1 216
N/A
2 372
+95%
2 698
+14%
3 583
+33%
4 557
+27%
5 497
+21%
6 365
+16%
6 567
+3%
8 168
+24%
8 119
-1%
Liabilities
Accounts Payable
35
65
81
117
199
262
347
310
379
285
Accrued Liabilities
45
49
59
86
82
97
149
142
163
147
Short-Term Debt
164
66
130
550
944
1 185
977
538
250
225
Current Portion of Long-Term Debt
0
63
69
0
0
120
70
144
152
345
Other Current Liabilities
43
46
52
77
160
156
255
179
139
118
Total Current Liabilities
286
290
391
831
1 385
1 819
1 798
1 313
1 083
1 121
Long-Term Debt
127
69
0
120
250
200
330
441
301
175
Deferred Income Tax
1
2
11
12
48
141
200
243
224
179
Minority Interest
0
5
40
112
170
201
209
243
236
227
Other Liabilities
10
11
12
7
9
9
32
28
31
33
Total Liabilities
424
N/A
377
-11%
455
+21%
1 083
+138%
1 861
+72%
2 371
+27%
2 568
+8%
2 268
-12%
1 875
-17%
1 734
-8%
Equity
Common Stock
149
186
558
558
558
558
557
556
612
612
Retained Earnings
633
839
1 101
1 412
1 782
2 218
2 906
3 624
4 047
4 147
Additional Paid In Capital
11
970
585
531
486
444
369
280
1 781
1 781
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
8
23
14
Treasury Stock
0
0
0
0
131
93
48
170
170
170
Other Equity
0
0
0
0
0
0
13
0
0
1
Total Equity
792
N/A
1 995
+152%
2 243
+12%
2 501
+11%
2 695
+8%
3 126
+16%
3 797
+21%
4 299
+13%
6 293
+46%
6 385
+1%
Total Liabilities & Equity
1 216
N/A
2 372
+95%
2 698
+14%
3 583
+33%
4 557
+27%
5 497
+21%
6 365
+16%
6 567
+3%
8 168
+24%
8 119
-1%
Shares Outstanding
Common Shares Outstanding
446
558
558
558
552
552
552
553
609
609

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.